{"id":928233,"date":"2026-01-16T16:06:00","date_gmt":"2026-01-16T21:06:00","guid":{"rendered":"https:\/\/www.marketnewsdesk.com\/index.php\/stoke-therapeutics-announces-inducement-grants-under-nasdaq-listing-rule-5635c4-8\/"},"modified":"2026-01-16T16:06:00","modified_gmt":"2026-01-16T21:06:00","slug":"stoke-therapeutics-announces-inducement-grants-under-nasdaq-listing-rule-5635c4-8","status":"publish","type":"post","link":"https:\/\/www.marketnewsdesk.com\/index.php\/stoke-therapeutics-announces-inducement-grants-under-nasdaq-listing-rule-5635c4-8\/","title":{"rendered":"Stoke Therapeutics Announces Inducement Grants Under Nasdaq Listing Rule 5635(C)(4)"},"content":{"rendered":"<p>        <!--.bwalignc { text-align: center; list-style-position: inside }body {font:normal small Arial,Helvetica,sans-serif;color:#000;background-color:#fff;padding:24px;margin:0;} a img {border:0;} h3 {font-size:medium;color:#000;margin:0 0 1em 0; text-align:center;}-->  <\/p>\n<p class=\"bwalignc\"><b>Stoke Therapeutics Announces Inducement Grants Under Nasdaq Listing Rule 5635(C)(4)<\/b><\/p>\n<p>BEDFORD, Mass.&#8211;(<a href=\"http:\/\/www.businesswire.com\">BUSINESS WIRE<\/a>)&#8211;<a rel=\"nofollow\" href=\"https:\/\/cts.businesswire.com\/ct\/CT?id=smartlink&amp;url=https%3A%2F%2Fwww.stoketherapeutics.com%2F&amp;esheet=54398778&amp;newsitemid=20260116352121&amp;lan=en-US&amp;anchor=Stoke+Therapeutics%2C+Inc.&amp;index=1&amp;md5=36626d67fbedd4df6c75f8ef8c6f9b72\">Stoke Therapeutics, Inc.<\/a> (Nasdaq: STOK) is a biotechnology company dedicated to restoring protein expression by harnessing the body\u2019s potential with RNA medicine and has a lead investigational medicine, zorevunersen, in development as a first-in-class potential disease-modifying treatment for Dravet syndrome. The Company today announced that, effective on January 15, 2026, it granted stock options to purchase an aggregate of 74,020 shares of common stock to nine new employees, as a material inducement to their employment in accordance with Nasdaq Listing Rule 5635(c)(4).<\/p>\n<p>\nThe stock options that were granted have an exercise price of $29.28 per share, which is equal to the closing price of Stoke\u2019s common stock on January 15, 2026. Each option will vest over a 4-year period, with 1\/4<sup>th<\/sup> of the shares underlying the employee\u2019s option vesting on the one-year anniversary of the applicable vesting commencement date and the remaining shares thereafter vesting monthly at a rate of 1\/48<sup>th<\/sup> of the shares underlying each employee\u2019s option over the following 36 months, subject to the employee\u2019s continued employment with Stoke on such vesting dates. The options have a term of 10 years and are subject to the terms and conditions of the 2023 Inducement Plan and the stock option agreement covering the grant.<\/p>\n<p><b>About Stoke Therapeutics<br \/>\n<br \/><\/b>Stoke Therapeutics (Nasdaq: STOK), is a biotechnology company dedicated to restoring protein expression by harnessing the body\u2019s potential with RNA medicine. Using Stoke\u2019s proprietary TANGO (Targeted Augmentation of Nuclear Gene Output) approach, Stoke is developing antisense oligonucleotides (ASOs) to selectively restore naturally-occurring protein levels. Stoke\u2019s first medicine in development, zorevunersen, has demonstrated the potential for disease modification in patients with Dravet syndrome and is currently being evaluated in a Phase 3 study. Stoke\u2019s initial focus are diseases of the central nervous system and the eye that are caused by a loss of ~50% of normal protein levels (haploinsufficiency). Proof of concept has been demonstrated in other organs, tissues, and systems, supporting broad potential for Stoke\u2019s proprietary approach. Stoke is headquartered in Bedford, Massachusetts. For more information, visit <a rel=\"nofollow\" href=\"https:\/\/cts.businesswire.com\/ct\/CT?id=smartlink&amp;url=https%3A%2F%2Fwww.stoketherapeutics.com%2F&amp;esheet=54398778&amp;newsitemid=20260116352121&amp;lan=en-US&amp;anchor=https%3A%2F%2Fwww.stoketherapeutics.com%2F&amp;index=2&amp;md5=2a7afd46395b8df65f6b5c2af2da3b76\">https:\/\/www.stoketherapeutics.com\/<\/a>.<\/p>\n<p><img decoding=\"async\" alt=\"\" src=\"https:\/\/cts.businesswire.com\/ct\/CT?id=bwnews&amp;sty=20260116352121r1&amp;sid=flmnd&amp;distro=nx&amp;lang=en\" style=\"width:0;height:0\" \/><span class=\"bwct31415\" \/><\/p>\n<p id=\"mmgallerylink\"><span id=\"mmgallerylink-phrase\">View source version on businesswire.com: <\/span><span id=\"mmgallerylink-link\"><a href=\"https:\/\/www.businesswire.com\/news\/home\/20260116352121\/en\/\" rel=\"nofollow\">https:\/\/www.businesswire.com\/news\/home\/20260116352121\/en\/<\/a><\/span><\/p>\n<p><b>Stoke Media &amp; Investor Contacts:<br \/>\n<\/b><br \/>Susan Willson<br \/>\n<br \/>Vice President, Corporate Communications<br \/>\n<br \/><a rel=\"nofollow\" href=\"mailto:swillson@stoketherapeutics.com\">swillson@stoketherapeutics.com<br \/>\n<\/a><br \/>415-509-8202<\/p>\n<p>\nDoug Snow<br \/>\n<br \/>Director, Communications &amp; Investor Relations<br \/>\n<br \/><a rel=\"nofollow\" href=\"mailto:IR@stoketherapeutics.com\">IR@stoketherapeutics.com<br \/>\n<\/a><br \/>508-642-6485<\/p>\n<p><b>KEYWORDS:<\/b> Massachusetts United States North America<\/p>\n<p><b>INDUSTRY KEYWORDS:<\/b> Health Genetics Other Science General Health Science Pharmaceutical Biotechnology<\/p>\n<p><b>MEDIA:<\/b><\/p>\n<table cellpadding=\"3\" cellspacing=\"3\">\n<tr>\n<td><font face=\"Arial\" size=\"2\"><b>Logo<\/b><\/font><\/td>\n<\/tr>\n<tr>\n<td><img decoding=\"async\" src=\"https:\/\/mms.businesswire.com\/media\/20260116352121\/en\/736143\/3\/Stoke_Logo1_-_CMYK_50percent.jpg\" alt=\"Logo\" \/><\/td>\n<\/tr>\n<tr>\n<td><font face=\"Arial\" size=\"2\"><\/font><\/td>\n<\/tr>\n<\/table>\n","protected":false},"excerpt":{"rendered":"<p>Stoke Therapeutics Announces Inducement Grants Under Nasdaq Listing Rule 5635(C)(4) BEDFORD, Mass.&#8211;(BUSINESS WIRE)&#8211;Stoke Therapeutics, Inc. (Nasdaq: STOK) is a biotechnology company dedicated to restoring protein expression by harnessing the body\u2019s potential with RNA medicine and has a lead investigational medicine, zorevunersen, in development as a first-in-class potential disease-modifying treatment for Dravet syndrome. The Company today announced that, effective on January 15, 2026, it granted stock options to purchase an aggregate of 74,020 shares of common stock to nine new employees, as a material inducement to their employment in accordance with Nasdaq Listing Rule 5635(c)(4). The stock options that were granted have an exercise price of $29.28 per share, which is equal to the closing price of Stoke\u2019s common stock on &hellip; <\/p>\n<p class=\"link-more\"><a href=\"https:\/\/www.marketnewsdesk.com\/index.php\/stoke-therapeutics-announces-inducement-grants-under-nasdaq-listing-rule-5635c4-8\/\" class=\"more-link\">Continue reading<span class=\"screen-reader-text\"> &#8220;Stoke Therapeutics Announces Inducement Grants Under Nasdaq Listing Rule 5635(C)(4)&#8221;<\/span><\/a><\/p>\n","protected":false},"author":2,"featured_media":0,"comment_status":"closed","ping_status":"closed","sticky":false,"template":"","format":"standard","meta":{"footnotes":""},"categories":[],"tags":[],"class_list":["post-928233","post","type-post","status-publish","format-standard","hentry"],"yoast_head":"<!-- This site is optimized with the Yoast SEO plugin v27.3 - https:\/\/yoast.com\/product\/yoast-seo-wordpress\/ -->\n<title>Stoke Therapeutics Announces Inducement Grants Under Nasdaq Listing Rule 5635(C)(4) - Market Newsdesk<\/title>\n<meta name=\"robots\" content=\"index, follow, max-snippet:-1, max-image-preview:large, max-video-preview:-1\" \/>\n<link rel=\"canonical\" href=\"https:\/\/www.marketnewsdesk.com\/index.php\/stoke-therapeutics-announces-inducement-grants-under-nasdaq-listing-rule-5635c4-8\/\" \/>\n<meta property=\"og:locale\" content=\"en_US\" \/>\n<meta property=\"og:type\" content=\"article\" \/>\n<meta property=\"og:title\" content=\"Stoke Therapeutics Announces Inducement Grants Under Nasdaq Listing Rule 5635(C)(4) - Market Newsdesk\" \/>\n<meta property=\"og:description\" content=\"Stoke Therapeutics Announces Inducement Grants Under Nasdaq Listing Rule 5635(C)(4) BEDFORD, Mass.&#8211;(BUSINESS WIRE)&#8211;Stoke Therapeutics, Inc. (Nasdaq: STOK) is a biotechnology company dedicated to restoring protein expression by harnessing the body\u2019s potential with RNA medicine and has a lead investigational medicine, zorevunersen, in development as a first-in-class potential disease-modifying treatment for Dravet syndrome. The Company today announced that, effective on January 15, 2026, it granted stock options to purchase an aggregate of 74,020 shares of common stock to nine new employees, as a material inducement to their employment in accordance with Nasdaq Listing Rule 5635(c)(4). The stock options that were granted have an exercise price of $29.28 per share, which is equal to the closing price of Stoke\u2019s common stock on &hellip; Continue reading &quot;Stoke Therapeutics Announces Inducement Grants Under Nasdaq Listing Rule 5635(C)(4)&quot;\" \/>\n<meta property=\"og:url\" content=\"https:\/\/www.marketnewsdesk.com\/index.php\/stoke-therapeutics-announces-inducement-grants-under-nasdaq-listing-rule-5635c4-8\/\" \/>\n<meta property=\"og:site_name\" content=\"Market Newsdesk\" \/>\n<meta property=\"article:published_time\" content=\"2026-01-16T21:06:00+00:00\" \/>\n<meta property=\"og:image\" content=\"https:\/\/cts.businesswire.com\/ct\/CT?id=bwnews&amp;sty=20260116352121r1&amp;sid=flmnd&amp;distro=nx&amp;lang=en\" \/>\n<meta name=\"author\" content=\"Newsdesk\" \/>\n<meta name=\"twitter:card\" content=\"summary_large_image\" \/>\n<meta name=\"twitter:label1\" content=\"Written by\" \/>\n\t<meta name=\"twitter:data1\" content=\"Newsdesk\" \/>\n\t<meta name=\"twitter:label2\" content=\"Est. reading time\" \/>\n\t<meta name=\"twitter:data2\" content=\"2 minutes\" \/>\n<script type=\"application\/ld+json\" class=\"yoast-schema-graph\">{\"@context\":\"https:\\\/\\\/schema.org\",\"@graph\":[{\"@type\":\"Article\",\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/stoke-therapeutics-announces-inducement-grants-under-nasdaq-listing-rule-5635c4-8\\\/#article\",\"isPartOf\":{\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/stoke-therapeutics-announces-inducement-grants-under-nasdaq-listing-rule-5635c4-8\\\/\"},\"author\":{\"name\":\"Newsdesk\",\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/#\\\/schema\\\/person\\\/482f27a394d4fda80ecb5499e519d979\"},\"headline\":\"Stoke Therapeutics Announces Inducement Grants Under Nasdaq Listing Rule 5635(C)(4)\",\"datePublished\":\"2026-01-16T21:06:00+00:00\",\"mainEntityOfPage\":{\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/stoke-therapeutics-announces-inducement-grants-under-nasdaq-listing-rule-5635c4-8\\\/\"},\"wordCount\":422,\"image\":{\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/stoke-therapeutics-announces-inducement-grants-under-nasdaq-listing-rule-5635c4-8\\\/#primaryimage\"},\"thumbnailUrl\":\"https:\\\/\\\/cts.businesswire.com\\\/ct\\\/CT?id=bwnews&amp;sty=20260116352121r1&amp;sid=flmnd&amp;distro=nx&amp;lang=en\",\"inLanguage\":\"en-US\"},{\"@type\":\"WebPage\",\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/stoke-therapeutics-announces-inducement-grants-under-nasdaq-listing-rule-5635c4-8\\\/\",\"url\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/stoke-therapeutics-announces-inducement-grants-under-nasdaq-listing-rule-5635c4-8\\\/\",\"name\":\"Stoke Therapeutics Announces Inducement Grants Under Nasdaq Listing Rule 5635(C)(4) - Market Newsdesk\",\"isPartOf\":{\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/#website\"},\"primaryImageOfPage\":{\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/stoke-therapeutics-announces-inducement-grants-under-nasdaq-listing-rule-5635c4-8\\\/#primaryimage\"},\"image\":{\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/stoke-therapeutics-announces-inducement-grants-under-nasdaq-listing-rule-5635c4-8\\\/#primaryimage\"},\"thumbnailUrl\":\"https:\\\/\\\/cts.businesswire.com\\\/ct\\\/CT?id=bwnews&amp;sty=20260116352121r1&amp;sid=flmnd&amp;distro=nx&amp;lang=en\",\"datePublished\":\"2026-01-16T21:06:00+00:00\",\"author\":{\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/#\\\/schema\\\/person\\\/482f27a394d4fda80ecb5499e519d979\"},\"breadcrumb\":{\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/stoke-therapeutics-announces-inducement-grants-under-nasdaq-listing-rule-5635c4-8\\\/#breadcrumb\"},\"inLanguage\":\"en-US\",\"potentialAction\":[{\"@type\":\"ReadAction\",\"target\":[\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/stoke-therapeutics-announces-inducement-grants-under-nasdaq-listing-rule-5635c4-8\\\/\"]}]},{\"@type\":\"ImageObject\",\"inLanguage\":\"en-US\",\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/stoke-therapeutics-announces-inducement-grants-under-nasdaq-listing-rule-5635c4-8\\\/#primaryimage\",\"url\":\"https:\\\/\\\/cts.businesswire.com\\\/ct\\\/CT?id=bwnews&amp;sty=20260116352121r1&amp;sid=flmnd&amp;distro=nx&amp;lang=en\",\"contentUrl\":\"https:\\\/\\\/cts.businesswire.com\\\/ct\\\/CT?id=bwnews&amp;sty=20260116352121r1&amp;sid=flmnd&amp;distro=nx&amp;lang=en\"},{\"@type\":\"BreadcrumbList\",\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/stoke-therapeutics-announces-inducement-grants-under-nasdaq-listing-rule-5635c4-8\\\/#breadcrumb\",\"itemListElement\":[{\"@type\":\"ListItem\",\"position\":1,\"name\":\"Home\",\"item\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/\"},{\"@type\":\"ListItem\",\"position\":2,\"name\":\"Stoke Therapeutics Announces Inducement Grants Under Nasdaq Listing Rule 5635(C)(4)\"}]},{\"@type\":\"WebSite\",\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/#website\",\"url\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/\",\"name\":\"Market Newsdesk\",\"description\":\"Latest Business News in Real Time\",\"potentialAction\":[{\"@type\":\"SearchAction\",\"target\":{\"@type\":\"EntryPoint\",\"urlTemplate\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/?s={search_term_string}\"},\"query-input\":{\"@type\":\"PropertyValueSpecification\",\"valueRequired\":true,\"valueName\":\"search_term_string\"}}],\"inLanguage\":\"en-US\"},{\"@type\":\"Person\",\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/#\\\/schema\\\/person\\\/482f27a394d4fda80ecb5499e519d979\",\"name\":\"Newsdesk\",\"image\":{\"@type\":\"ImageObject\",\"inLanguage\":\"en-US\",\"@id\":\"https:\\\/\\\/secure.gravatar.com\\\/avatar\\\/a0d0bd5b0f0ca12a265a459b13169dac35f33776d8501eda5e68844a366f2f46?s=96&d=mm&r=g\",\"url\":\"https:\\\/\\\/secure.gravatar.com\\\/avatar\\\/a0d0bd5b0f0ca12a265a459b13169dac35f33776d8501eda5e68844a366f2f46?s=96&d=mm&r=g\",\"contentUrl\":\"https:\\\/\\\/secure.gravatar.com\\\/avatar\\\/a0d0bd5b0f0ca12a265a459b13169dac35f33776d8501eda5e68844a366f2f46?s=96&d=mm&r=g\",\"caption\":\"Newsdesk\"},\"url\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/author\\\/newsdesk\\\/\"}]}<\/script>\n<!-- \/ Yoast SEO plugin. -->","yoast_head_json":{"title":"Stoke Therapeutics Announces Inducement Grants Under Nasdaq Listing Rule 5635(C)(4) - Market Newsdesk","robots":{"index":"index","follow":"follow","max-snippet":"max-snippet:-1","max-image-preview":"max-image-preview:large","max-video-preview":"max-video-preview:-1"},"canonical":"https:\/\/www.marketnewsdesk.com\/index.php\/stoke-therapeutics-announces-inducement-grants-under-nasdaq-listing-rule-5635c4-8\/","og_locale":"en_US","og_type":"article","og_title":"Stoke Therapeutics Announces Inducement Grants Under Nasdaq Listing Rule 5635(C)(4) - Market Newsdesk","og_description":"Stoke Therapeutics Announces Inducement Grants Under Nasdaq Listing Rule 5635(C)(4) BEDFORD, Mass.&#8211;(BUSINESS WIRE)&#8211;Stoke Therapeutics, Inc. (Nasdaq: STOK) is a biotechnology company dedicated to restoring protein expression by harnessing the body\u2019s potential with RNA medicine and has a lead investigational medicine, zorevunersen, in development as a first-in-class potential disease-modifying treatment for Dravet syndrome. The Company today announced that, effective on January 15, 2026, it granted stock options to purchase an aggregate of 74,020 shares of common stock to nine new employees, as a material inducement to their employment in accordance with Nasdaq Listing Rule 5635(c)(4). The stock options that were granted have an exercise price of $29.28 per share, which is equal to the closing price of Stoke\u2019s common stock on &hellip; Continue reading \"Stoke Therapeutics Announces Inducement Grants Under Nasdaq Listing Rule 5635(C)(4)\"","og_url":"https:\/\/www.marketnewsdesk.com\/index.php\/stoke-therapeutics-announces-inducement-grants-under-nasdaq-listing-rule-5635c4-8\/","og_site_name":"Market Newsdesk","article_published_time":"2026-01-16T21:06:00+00:00","og_image":[{"url":"https:\/\/cts.businesswire.com\/ct\/CT?id=bwnews&amp;sty=20260116352121r1&amp;sid=flmnd&amp;distro=nx&amp;lang=en","type":"","width":"","height":""}],"author":"Newsdesk","twitter_card":"summary_large_image","twitter_misc":{"Written by":"Newsdesk","Est. reading time":"2 minutes"},"schema":{"@context":"https:\/\/schema.org","@graph":[{"@type":"Article","@id":"https:\/\/www.marketnewsdesk.com\/index.php\/stoke-therapeutics-announces-inducement-grants-under-nasdaq-listing-rule-5635c4-8\/#article","isPartOf":{"@id":"https:\/\/www.marketnewsdesk.com\/index.php\/stoke-therapeutics-announces-inducement-grants-under-nasdaq-listing-rule-5635c4-8\/"},"author":{"name":"Newsdesk","@id":"https:\/\/www.marketnewsdesk.com\/#\/schema\/person\/482f27a394d4fda80ecb5499e519d979"},"headline":"Stoke Therapeutics Announces Inducement Grants Under Nasdaq Listing Rule 5635(C)(4)","datePublished":"2026-01-16T21:06:00+00:00","mainEntityOfPage":{"@id":"https:\/\/www.marketnewsdesk.com\/index.php\/stoke-therapeutics-announces-inducement-grants-under-nasdaq-listing-rule-5635c4-8\/"},"wordCount":422,"image":{"@id":"https:\/\/www.marketnewsdesk.com\/index.php\/stoke-therapeutics-announces-inducement-grants-under-nasdaq-listing-rule-5635c4-8\/#primaryimage"},"thumbnailUrl":"https:\/\/cts.businesswire.com\/ct\/CT?id=bwnews&amp;sty=20260116352121r1&amp;sid=flmnd&amp;distro=nx&amp;lang=en","inLanguage":"en-US"},{"@type":"WebPage","@id":"https:\/\/www.marketnewsdesk.com\/index.php\/stoke-therapeutics-announces-inducement-grants-under-nasdaq-listing-rule-5635c4-8\/","url":"https:\/\/www.marketnewsdesk.com\/index.php\/stoke-therapeutics-announces-inducement-grants-under-nasdaq-listing-rule-5635c4-8\/","name":"Stoke Therapeutics Announces Inducement Grants Under Nasdaq Listing Rule 5635(C)(4) - Market Newsdesk","isPartOf":{"@id":"https:\/\/www.marketnewsdesk.com\/#website"},"primaryImageOfPage":{"@id":"https:\/\/www.marketnewsdesk.com\/index.php\/stoke-therapeutics-announces-inducement-grants-under-nasdaq-listing-rule-5635c4-8\/#primaryimage"},"image":{"@id":"https:\/\/www.marketnewsdesk.com\/index.php\/stoke-therapeutics-announces-inducement-grants-under-nasdaq-listing-rule-5635c4-8\/#primaryimage"},"thumbnailUrl":"https:\/\/cts.businesswire.com\/ct\/CT?id=bwnews&amp;sty=20260116352121r1&amp;sid=flmnd&amp;distro=nx&amp;lang=en","datePublished":"2026-01-16T21:06:00+00:00","author":{"@id":"https:\/\/www.marketnewsdesk.com\/#\/schema\/person\/482f27a394d4fda80ecb5499e519d979"},"breadcrumb":{"@id":"https:\/\/www.marketnewsdesk.com\/index.php\/stoke-therapeutics-announces-inducement-grants-under-nasdaq-listing-rule-5635c4-8\/#breadcrumb"},"inLanguage":"en-US","potentialAction":[{"@type":"ReadAction","target":["https:\/\/www.marketnewsdesk.com\/index.php\/stoke-therapeutics-announces-inducement-grants-under-nasdaq-listing-rule-5635c4-8\/"]}]},{"@type":"ImageObject","inLanguage":"en-US","@id":"https:\/\/www.marketnewsdesk.com\/index.php\/stoke-therapeutics-announces-inducement-grants-under-nasdaq-listing-rule-5635c4-8\/#primaryimage","url":"https:\/\/cts.businesswire.com\/ct\/CT?id=bwnews&amp;sty=20260116352121r1&amp;sid=flmnd&amp;distro=nx&amp;lang=en","contentUrl":"https:\/\/cts.businesswire.com\/ct\/CT?id=bwnews&amp;sty=20260116352121r1&amp;sid=flmnd&amp;distro=nx&amp;lang=en"},{"@type":"BreadcrumbList","@id":"https:\/\/www.marketnewsdesk.com\/index.php\/stoke-therapeutics-announces-inducement-grants-under-nasdaq-listing-rule-5635c4-8\/#breadcrumb","itemListElement":[{"@type":"ListItem","position":1,"name":"Home","item":"https:\/\/www.marketnewsdesk.com\/"},{"@type":"ListItem","position":2,"name":"Stoke Therapeutics Announces Inducement Grants Under Nasdaq Listing Rule 5635(C)(4)"}]},{"@type":"WebSite","@id":"https:\/\/www.marketnewsdesk.com\/#website","url":"https:\/\/www.marketnewsdesk.com\/","name":"Market Newsdesk","description":"Latest Business News in Real Time","potentialAction":[{"@type":"SearchAction","target":{"@type":"EntryPoint","urlTemplate":"https:\/\/www.marketnewsdesk.com\/?s={search_term_string}"},"query-input":{"@type":"PropertyValueSpecification","valueRequired":true,"valueName":"search_term_string"}}],"inLanguage":"en-US"},{"@type":"Person","@id":"https:\/\/www.marketnewsdesk.com\/#\/schema\/person\/482f27a394d4fda80ecb5499e519d979","name":"Newsdesk","image":{"@type":"ImageObject","inLanguage":"en-US","@id":"https:\/\/secure.gravatar.com\/avatar\/a0d0bd5b0f0ca12a265a459b13169dac35f33776d8501eda5e68844a366f2f46?s=96&d=mm&r=g","url":"https:\/\/secure.gravatar.com\/avatar\/a0d0bd5b0f0ca12a265a459b13169dac35f33776d8501eda5e68844a366f2f46?s=96&d=mm&r=g","contentUrl":"https:\/\/secure.gravatar.com\/avatar\/a0d0bd5b0f0ca12a265a459b13169dac35f33776d8501eda5e68844a366f2f46?s=96&d=mm&r=g","caption":"Newsdesk"},"url":"https:\/\/www.marketnewsdesk.com\/index.php\/author\/newsdesk\/"}]}},"_links":{"self":[{"href":"https:\/\/www.marketnewsdesk.com\/index.php\/wp-json\/wp\/v2\/posts\/928233","targetHints":{"allow":["GET"]}}],"collection":[{"href":"https:\/\/www.marketnewsdesk.com\/index.php\/wp-json\/wp\/v2\/posts"}],"about":[{"href":"https:\/\/www.marketnewsdesk.com\/index.php\/wp-json\/wp\/v2\/types\/post"}],"author":[{"embeddable":true,"href":"https:\/\/www.marketnewsdesk.com\/index.php\/wp-json\/wp\/v2\/users\/2"}],"replies":[{"embeddable":true,"href":"https:\/\/www.marketnewsdesk.com\/index.php\/wp-json\/wp\/v2\/comments?post=928233"}],"version-history":[{"count":0,"href":"https:\/\/www.marketnewsdesk.com\/index.php\/wp-json\/wp\/v2\/posts\/928233\/revisions"}],"wp:attachment":[{"href":"https:\/\/www.marketnewsdesk.com\/index.php\/wp-json\/wp\/v2\/media?parent=928233"}],"wp:term":[{"taxonomy":"category","embeddable":true,"href":"https:\/\/www.marketnewsdesk.com\/index.php\/wp-json\/wp\/v2\/categories?post=928233"},{"taxonomy":"post_tag","embeddable":true,"href":"https:\/\/www.marketnewsdesk.com\/index.php\/wp-json\/wp\/v2\/tags?post=928233"}],"curies":[{"name":"wp","href":"https:\/\/api.w.org\/{rel}","templated":true}]}}